These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 36334653

  • 1. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

  • 2. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R.
    Transplantation; 2010 Sep 15; 90(5):564-70. PubMed ID: 20555307
    [Abstract] [Full Text] [Related]

  • 3. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.
    Burns DM, Rana S, Martin E, Nagra S, Ward J, Osman H, Bell AI, Moss P, Russell NH, Craddock CF, Fox CP, Chaganti S.
    Bone Marrow Transplant; 2016 Jun 15; 51(6):825-32. PubMed ID: 26901708
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J, Yong MK, Greenwood M, Kong DCM, Chen SCA, Rawlinson W, Slavin M.
    Rev Med Virol; 2020 Jul 15; 30(4):e2108. PubMed ID: 32301566
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Jul 15; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 6. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
    Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB.
    Leuk Lymphoma; 2019 Jul 15; 60(7):1693-1696. PubMed ID: 30741059
    [Abstract] [Full Text] [Related]

  • 7. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, Sun A, Wu D.
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb 15; 37(2):138-43. PubMed ID: 27014984
    [Abstract] [Full Text] [Related]

  • 8. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A.
    Pediatr Int; 2017 Sep 15; 59(9):973-978. PubMed ID: 28581032
    [Abstract] [Full Text] [Related]

  • 9. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY, Dong YJ, Yin Y, Xu WL, Liang ZY, Wang Q, Li Y, Liu W, Ou JP, Ren HY.
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov 14; 42(11):904-910. PubMed ID: 35045651
    [Abstract] [Full Text] [Related]

  • 10. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
    Delapierre B, Reman O, Dina J, Breuil C, Bellal M, Johnson-Ansah H, Gac AC, Damaj G, Chantepie S.
    Curr Res Transl Med; 2019 Nov 14; 67(4):145-148. PubMed ID: 30871955
    [Abstract] [Full Text] [Related]

  • 11. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.
    Transpl Infect Dis; 2019 Dec 14; 21(6):e13182. PubMed ID: 31556214
    [Abstract] [Full Text] [Related]

  • 12. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
    Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.
    Biol Blood Marrow Transplant; 2010 Feb 14; 16(2):287-91. PubMed ID: 19835968
    [Abstract] [Full Text] [Related]

  • 13. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
    Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N, Touloumenidou T, Zerva P, Kika F, Iskas M, Batsis I, Mallouri D, Yannaki E, Anagnostopoulos A, Sakellari I.
    Int J Mol Sci; 2023 Nov 07; 24(22):. PubMed ID: 38003218
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation.
    Pagliuca S, Bommier C, Michonneau D, Meignin V, Salmona M, Robin M, Prata PH, Xhaard A, de Fontbrune FS, Feghoul L, Dhedin N, de Latour RP, Caillat-Zucman S, Goff JL, Socié G.
    Biol Blood Marrow Transplant; 2019 Dec 07; 25(12):2490-2500. PubMed ID: 31421238
    [Abstract] [Full Text] [Related]

  • 15. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 07; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 16. Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.
    Su YY, Yu YF, Yan ZY, Zhao YJ, Lou JW, Xue F, Xu M, Feng Q, Ji XB, Dong XY, Wang W, Liu CF, Peng J, Liu XG.
    Diagn Pathol; 2024 Sep 07; 19(1):122. PubMed ID: 39244586
    [Abstract] [Full Text] [Related]

  • 17. Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation.
    Marzolini MAV, Wilson AJ, Sanchez E, Carpenter B, Chakraverty R, Hough R, Kottaridis P, Morris EC, Thomson KJ, Peggs KS.
    Transplant Cell Ther; 2021 Aug 07; 27(8):682.e1-682.e12. PubMed ID: 33962069
    [Abstract] [Full Text] [Related]

  • 18. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
    Chen DB, Liu XY, Kong FZ, Jiang Q, Shen DH.
    J Clin Pathol; 2021 Nov 07; 74(11):697-703. PubMed ID: 34011618
    [Abstract] [Full Text] [Related]

  • 19. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY, Mo XD, Xu LP, Zhang XH, Wang Y, Liu KY, Chang YJ, Zhao XY, Huang XJ.
    Ann Hematol; 2020 Nov 07; 99(11):2649-2657. PubMed ID: 32206854
    [Abstract] [Full Text] [Related]

  • 20. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY, Zhao SS, Wang XK, Wang L, Wang FY, Fang S, Liu ZX, Guan LX, Liu YC, Ding Y, Dou LP, Wang LL, Gao CJ.
    Ann Transplant; 2019 Apr 03; 24():175-184. PubMed ID: 30940797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.